Harmony Biosciences (HRMY) Appoints Jeffrey M. Dayno as President and CEO
Get Alerts HRMY Hot Sheet
Join SI Premium – FREE
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that
Harmony Board Chairman,
"
With the appointment,
"After 12 years as a practicing neurologist taking care of patients, followed by 25 years in the industry touching every aspect of the business, I have seen the impact that developing and delivering innovative treatments can have on patients and their families. I am honored that the Board has asked me to lead the company forward in our next phase of growth," said
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Amneal Pharmaceuticals (AMRX) Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Fortress Transportation (FTAI) and LATAM Airlines Group S.A. Engineer Perpetual Power Program
Create E-mail Alert Related Categories
Corporate News, Management ChangesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!